Journal article 260 views 64 downloads
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Endocrinology and Metabolism, Volume: 38, Issue: 1, Pages: 25 - 33
Swansea University Author:
Steve Bain
-
PDF | Version of Record
Copyright © 2023 Korean Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
Download (314.93KB)
DOI (Published version): 10.3803/enm.2022.1642
Abstract
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations b...
| Published in: | Endocrinology and Metabolism |
|---|---|
| ISSN: | 2093-596X 2093-5978 |
| Published: |
Korean Endocrine Society
2023
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa62654 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease. |
|---|---|
| Keywords: |
Glucagon-like peptide 1; Diabetes mellitus, type 2; Renal insufficiency, chronic |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
1 |
| Start Page: |
25 |
| End Page: |
33 |